Cited 14 times in
Evaluating immunologic response and clinical deterioration in treatment-naïve patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최준용 | - |
dc.date.accessioned | 2014-12-18T09:17:53Z | - |
dc.date.available | 2014-12-18T09:17:53Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1525-4135 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/87907 | - |
dc.description.abstract | BACKGROUND: HIV-1 group M viruses diverge 25%-35% in envelope, important for viral attachment during infection, and 10%-15% in the pol region, under selection pressure from common antiretrovirals. In Asia, subtypes B and CRF01_AE are common genotypes. Our objectives were to determine whether clinical, immunological, or virological treatment responses differed by genotype in treatment-naive patients initiating first-line therapy. METHODS: Prospectively collected longitudinal data from patients in Thailand, Hong Kong, Malaysia, Japan, Taiwan, and South Korea were provided for analysis. Covariates included demographics, hepatitis B and C coinfections, baseline CD4 T lymphocyte count, and plasma HIV-1 RNA levels. Clinical deterioration (a new diagnosis of Centers for Disease Control and Prevention category B/AIDS-defining illness or death) was assessed by proportional hazards models. Surrogate endpoints were 12-month change in CD4 cell count and virologic suppression post therapy, evaluated by linear and logistic regression, respectively. RESULTS: Of 1105 patients, 1036 (93.8%) infected with CRF01_AE or subtype B were eligible for inclusion in clinical deterioration analyses and contributed 1546.7 person-years of follow-up (median: 413 days, interquartile range: 169-672 days). Patients >40 years demonstrated smaller immunological increases (P = 0.002) and higher risk of clinical deterioration (hazard ratio = 2.17; P = 0.008). Patients with baseline CD4 cell counts >200 cells per microliter had lower risk of clinical deterioration (hazard ratio = 0.373; P = 0.003). A total of 532 patients (48.1% of eligible) had CD4 counts available at baseline and 12 months post therapy for inclusion in immunolgic analyses. Patients infected with subtype B had larger increases in CD4 counts at 12 months (P = 0.024). A total of 530 patients (48.0% of eligible) were included in virological analyses with no differences in response found between genotypes. CONCLUSIONS: Results suggest that patients infected with CRF01_AE have reduced immunologic response to therapy at 12 months, compared with subtype B-infected counterparts. Clinical deterioration was associated with low baseline CD4 counts and older age. The lack of differences in virologic outcomes suggests that all patients have opportunities for virological suppression. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antiretroviral Therapy, Highly Active* | - |
dc.subject.MESH | Asia | - |
dc.subject.MESH | CD4 Lymphocyte Count | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | HIV Infections/drug therapy* | - |
dc.subject.MESH | HIV Infections/immunology | - |
dc.subject.MESH | HIV Infections/virology | - |
dc.subject.MESH | HIV-1/classification | - |
dc.subject.MESH | HIV-1/genetics* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Logistic Models | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | RNA, Viral/blood | - |
dc.title | Evaluating immunologic response and clinical deterioration in treatment-naïve patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Rebecca A. Oyomopito | - |
dc.contributor.googleauthor | Patrick CK. Li | - |
dc.contributor.googleauthor | Somnuek Sungkanuparph | - |
dc.contributor.googleauthor | Praphan Phanuphak | - |
dc.contributor.googleauthor | Kok Keng Tee | - |
dc.contributor.googleauthor | Thira Sirisanthana | - |
dc.contributor.googleauthor | Pacharee Kantipong | - |
dc.contributor.googleauthor | Shinichi Oka | - |
dc.contributor.googleauthor | Chris KC. Lee | - |
dc.contributor.googleauthor | Adeeba Kamarulzaman | - |
dc.contributor.googleauthor | Jun Yong Choi | - |
dc.contributor.googleauthor | Annette H. Sohn | - |
dc.contributor.googleauthor | Matthew Law | - |
dc.contributor.googleauthor | Yi-Ming A. Chen | - |
dc.identifier.doi | 10.1097/QAI.0b013e31827a2e8f | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04191 | - |
dc.relation.journalcode | J01195 | - |
dc.identifier.eissn | 1944-7884 | - |
dc.identifier.pmid | 23138836 | - |
dc.subject.keyword | HIV-1 | - |
dc.subject.keyword | Asia | - |
dc.subject.keyword | genotype | - |
dc.subject.keyword | CRF01_AE | - |
dc.subject.keyword | subtype B | - |
dc.contributor.alternativeName | Choi, Jun Yong | - |
dc.contributor.affiliatedAuthor | Choi, Jun Yong | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 62 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 293 | - |
dc.citation.endPage | 300 | - |
dc.identifier.bibliographicCitation | JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, Vol.62(3) : 293-300, 2013 | - |
dc.identifier.rimsid | 32606 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.